{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:08:55Z","timestamp":1784182135392,"version":"3.55.0"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Breast cancer progression and resistance to therapy are strongly influenced by immune evasion within the tumor microenvironment. Immune checkpoint signaling is a major mechanism by which cancer cells evade immune surveillance, thereby promoting tumor progression and reducing the effectiveness of immunotherapy. Recent evidence suggests that extracellular vesicles (EVs) are important mediators of communication between tumor, stromal, and immune cells, enabling the transfer of proteins, nucleic acids, lipids, and other bioactive molecules that regulate immune responses. This review discusses current knowledge on the role of EVs in immune checkpoint regulation in breast cancer, with an emphasis on both programmed death-ligand 1 (PD-L1)-dependent and additional immunosuppressive pathways that collectively contribute to immune escape. A literature review was conducted using PubMed, Google Scholar, and Web of Science, focusing on studies from the past decade related to EV biology, immune checkpoints, and breast cancer. Findings from multiple studies indicate that tumor-derived EVs contribute to immunosuppression by impairing T-cell function, promoting immune tolerance, facilitating metastatic progression, and supporting resistance to immunotherapy. Importantly, EV-mediated effects are different for the breast cancer subtypes, which may play a role in treatment response, disease progression, and clinical outcomes. EVs also show potential as minimally invasive biomarkers for disease monitoring and as therapeutic targets or delivery systems for precision medicine. Overall, this review highlights current evidence on EV-mediated immune checkpoint regulation in breast cancer, highlighting PD-L1 and CTLA-4associated mechanisms as key drivers of immune evasion and promising targets for precision immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1872143","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:51Z","timestamp":1784180271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators"],"prefix":"10.3389","volume":"17","author":[{"given":"Jayenth","family":"Jayachandran","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE)","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajit","family":"Pathak","sequence":"additional","affiliation":[{"name":"Medical Biotechnology Lab, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI)","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulya","family":"Maizetova","sequence":"additional","affiliation":[{"name":"Cell Lab 7","place":["Masdar City, Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunkumar","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE)","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antara","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Medical Biotechnology Lab, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI)","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim K","family":"Duttaroy","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Institute of Medical Sciences, Faculty of Medicine, University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cac2.12207","article-title":"Global patterns of breast cancer incidence and mortality: a population\u2010based cancer registry data analysis from 2000 to 2020","volume":"41","author":"Lei","year":"2021","journal-title":"Cancer Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071102","article-title":"Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies","volume":"17","author":"Carvalho","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1442888","article-title":"TME and cancer metastasis: molecular mechanisms and therapeutic implications","volume":"15","author":"Biray Avci","year":"2024","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13046-025-03527-z","article-title":"Crosstalk between heterogeneous cancer-associated fibroblast subpopulations and the immune system in breast cancer: key players and promising therapeutic targets","volume":"44","author":"Liu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the TME: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13058-025-02131-5","article-title":"Modulating phosphodiesterase-5 activity to suppress the immunosuppressive mechanisms of myeloid-derived suppressor cells in breast cancer","volume":"27","author":"Guo","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-025-02181-3","article-title":"Molecular classification of hormone receptor-positive \/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s13402-021-00634-9","article-title":"The TME as driver of stemness and therapeutic resistance in breast cancer: new challenges and therapeutic opportunities","volume":"44","author":"Mehraj","year":"2021","journal-title":"Cell Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413457","article-title":"TME On-Chip and single-cell analysis reveal synergistic stromal\u2013immune crosstalk on breast cancer progression","volume":"12","author":"Ravi","year":"2025","journal-title":"Adv Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-025-00672-1","article-title":"Multi-omics analyses of the heterogenous immune microenvironment in triple-negative breast cancer implicate UQCRFS1 potentiates tumor progression","volume":"14","author":"Tang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092053","article-title":"The role of TME in cancer metastasis: molecular mechanisms and therapeutic opportunities","volume":"13","author":"Neophytou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314937","article-title":"Genetic heterogeneity, TME and immunotherapy in triple-negative breast cancer","volume":"23","author":"Kudelova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/path.6395","article-title":"Extracellular matrix cancer\u2010associated fibroblasts promote stromal fibrosis and immune exclusion in triple\u2010negative breast cancer","volume":"265","author":"Lu","year":"2025","journal-title":"J Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116224","article-title":"Guardians and mediators of metastasis: exploring T lymphocytes, myeloid-derived suppressor cells, and tumor-associated macrophages in the breast cancer microenvironment","volume":"25","author":"Ruocco","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/0008-5472.CAN-21-3714","article-title":"Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer","volume":"82","author":"Singh","year":"2022","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","article-title":"T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution","volume":"43","author":"Yang","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061305","article-title":"The peripheral immune landscape of breast cancer: clinical findings and in vitro models for biomarker discovery","volume":"13","author":"Batalha","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1360507","article-title":"Integrative analysis identifies cancer cell-intrinsic RARRES1 as a predictor of prognosis and immune response in triple-negative breast cancer","volume":"15","author":"Yu","year":"2024","journal-title":"Front Gen"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun Sig"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","article-title":"PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies","volume":"23","author":"Jin","year":"2024","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7040149","article-title":"Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3, and LAG-3 immune checkpoints in CD4+ T cells","volume":"7","author":"Saleh","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125851","article-title":"Immune-checkpoint expression in breast cancer patients: clinicopathological implications: a retrospective case series study","volume":"26","author":"Quiroz-Bola\u00f1os","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.563044","article-title":"The expression pattern and clinical significance of the immune checkpoint regulator VISTA in human breast cancer","volume":"11","author":"Xie","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-025-02233-w","article-title":"EVs in tumor immunity: mechanisms and novel insights","volume":"24","author":"Kuang","year":"2025","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/biom15081195","article-title":"EVs derived from breast cancer cells: emerging biomarkers of tumor progression and metastasis","volume":"15","author":"Bernatova","year":"2025","journal-title":"Biomolecules"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144990","article-title":"Selectively-packaged proteins in breast cancer EVs involved in metastasis","volume":"21","author":"Dalla","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417357","article-title":"Effect of EVs derived from tumor cells on immune evasion","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01370-3","article-title":"Tumor immune escape: EVs roles and therapeutics application","volume":"22","author":"Ahmadi","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/biology12010110","article-title":"EVs: new classification and tumor immunosuppression","volume":"12","author":"Sheta","year":"2023","journal-title":"Biol (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1038\/s41375-020-01041-z","article-title":"Extracellular microvesicles\/exosomes: discovery, disbelief, acceptance, and the future","volume":"34","author":"Ratajczak","year":"2020","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1154576","article-title":"EVs: a dive into their role in the TME and cancer progression","volume":"11","author":"Lopez","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/path.6138","article-title":"EVs arising from apoptosis: forms, functions, and applications","volume":"260","author":"Gregory","year":"2023","journal-title":"J Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13046-025-03418-3","article-title":"Characterization of extracellular vesicle-associated DNA and proteins derived from organotropic metastatic breast cancer cells","volume":"44","author":"Nadeau","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125430","article-title":"Unveiling the involvement of extracellular vesicles in breast cancer\u2019s organotrophic metastasis: molecular mechanisms and translational prospects","volume":"26","author":"Shang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1548724","article-title":"Intercellular communication between extracellular vesicles from conditioned macrophages and breast cancer cells drives endocrine therapy resistance","volume":"13","author":"Rodriguez-Baili","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101286","article-title":"Extracellular vesicle-mediated transport: reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis","volume":"15","author":"Brena","year":"2022","journal-title":"Transl Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194879","article-title":"Extracellular vesicles in triple\u2013negative breast cancer: immune regulation, biomarkers, and immunotherapeutic potential","volume":"15","author":"Das","year":"2023","journal-title":"Cancers"},{"key":"B45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-019-0965-7","article-title":"EVs-mediated intercellular communication: roles in the TME and anti-cancer drug resistance","volume":"18","author":"Maacha","year":"2019","journal-title":"Mol Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.devcel.2021.05.014","article-title":"Oncogene-regulated release of EVs","volume":"56","author":"Kilinc","year":"2021","journal-title":"Dev Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02282-1","article-title":"EVs in cancer\u00b4s communication: messages we can read and how to answer","volume":"24","author":"Semeradtova","year":"2025","journal-title":"Mol Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11427-024-2852-9","article-title":"EVs in cancer progression: mechanisms and significance","volume":"69","author":"Gao","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012646","article-title":"Small EVs from hypoxic triple-negative breast cancer cells induce oxygen-dependent cell invasion","volume":"23","author":"Pachane","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810216","article-title":"Hypoxia-induced adaptations of N-glycomes and proteomes in breast cancer cells and their secreted EVs","volume":"25","author":"Peng","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.devcel.2020.07.014","article-title":"Small extracellular vesicle regulation of mitochondrial dynamics reprograms a hypoxic TME","volume":"55","author":"Bertolini","year":"2020","journal-title":"Dev Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-025-03471-y","article-title":"Small EVs: messengers at the service of breast cancer agenda in the primary and distant microenvironments","volume":"44","author":"Galardi","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213993","article-title":"Tumor-derived exosomes and their role in breast cancer metastasis","volume":"23","author":"Huang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","article-title":"Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management","volume":"14","author":"Hansen","year":"2024","journal-title":"Theranostics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.20517\/cdr.2020.11","article-title":"A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy","volume":"3","author":"Fujiwara","year":"2020","journal-title":"Cancer Drug Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112941","article-title":"Proteomic profiling of EVs released by leptin-treated breast cancer cells: a potential role in cancer metabolism","volume":"23","author":"Gelsomino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1561464","article-title":"Extracellular vesicles in triple-negative breast cancer: current updates, challenges, and future prospects","volume":"14","author":"Tiwari","year":"2025","journal-title":"Front Mol Biosci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051141","article-title":"The role of extracellular vesicles in the hallmarks of cancer and drug resistance","volume":"9","author":"Xavier","year":"2020","journal-title":"Cells"},{"key":"B59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-023-01741-x","article-title":"Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis","volume":"22","author":"Lee","year":"2023","journal-title":"Mol Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601266","article-title":"Cancer cell-derived EVs: a potential target for overcoming tumor immunotherapy resistance and immune evasion strategies","volume":"16","author":"Ahn","year":"2025","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201901779","article-title":"EVs in cancer immune microenvironment and cancer immunotherapy","volume":"6","author":"Xie","year":"2019","journal-title":"Adv Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581964","article-title":"Tumor-derived vesicles in immune modulation: focus on signaling pathways","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548535","article-title":"Tumor-derived EVs: key drivers of immunomodulation in breast cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70448","article-title":"Role of triple-negative breast cancer-derived EVs in metastasis: implications for therapeutics and biomarker development","volume":"29","author":"Wan","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.900155","article-title":"Crosstalk of exosomal non-coding RNAs in the tumor microenvironment: novel frontiers","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immuno"},{"key":"B66","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/13543784.2024.2360209","article-title":"The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy","volume":"33","author":"Aghakhani","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12964-021-00816-w","article-title":"Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies","volume":"20","author":"Liu","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061356","article-title":"EVs and PD-L1\u2014A review of complex immunoregulatory properties and clinical importance","volume":"13","author":"Kie\u0142bowski","year":"2025","journal-title":"Biomedicines"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm7269","article-title":"Tumor extracellular vesicle\u2013derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming","volume":"17","author":"Ma","year":"2025","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-021-01490-9","article-title":"Circulating EVs expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma","volume":"21","author":"Serrat\u00ec","year":"2022","journal-title":"Mol Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.trecan.2021.03.003","article-title":"Extracellular and nuclear PD-L1 in modulating cancer immunotherapy","volume":"7","author":"Xiong","year":"2021","journal-title":"Trends Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.7150\/thno.68864","article-title":"Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1","volume":"12","author":"Lee","year":"2022","journal-title":"Theranostics"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1016\/j.ymthe.2025.05.038","article-title":"Cancer-derived extracellular vesicles in natural killer cell immune evasion: molecular mechanisms and therapeutic insights","volume":"33","author":"Coleborn","year":"2025","journal-title":"Mol Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1038\/s41467-022-31250-2","article-title":"Breast cancer cell-derived EVs promote CD8+\u2009T cell exhaustion via TGF-\u03b2 type II receptor signaling","volume":"13","author":"Xie","year":"2022","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12672-024-01007-y","article-title":"Extracellular vesicle-mediated drug delivery in breast cancer theranostics","volume":"15","author":"Abdul-Rahman","year":"2024","journal-title":"Discov Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s13287-025-04476-2","article-title":"In-vitro immunomodulatory efficacy of EVs derived from TGF-\u03b21\/IFN-\u03b3 dual licensed human bone marrow mesenchymal stromal cells","volume":"16","author":"Wang","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41590-021-00899-0","article-title":"EVs in immunomodulation and tumor progression","volume":"22","author":"Marar","year":"2021","journal-title":"Nat Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12935-025-03809-8","article-title":"Emerging roles of non-coding RNA derived from EVs in regulating PD-1\/PD-L1 pathway: insights into cancer immunotherapy and clinical applications","volume":"25","author":"Zhang","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123558","article-title":"Immune regulation by dendritic cell EVs in cancer immunotherapy and vaccines","volume":"12","author":"Fern\u00e1ndez-Delgado","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01152","article-title":"Immunotherapy based on dendritic cell-targeted\/-derived EVs-a novel strategy for enhancement of the anti-tumor immune response","volume":"10","author":"Markov","year":"2019","journal-title":"Front Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021205","article-title":"EVs and immunity: At the crossroads of cell communication","volume":"25","author":"Aloi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221131647","article-title":"Cancer-associated fibroblasts communicate with breast tumor cells through EVs in tumor development","volume":"21","author":"Castillo-Sanchez","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"B84","doi-asserted-by":"publisher","first-page":"30943","DOI":"10.1021\/acsnano.3c12967","article-title":"Tumor-derived EVs enable tumor tropism chemo-genetherapy for local immune activation in triple-negative breast cancer","volume":"18","author":"Peng","year":"2024","journal-title":"ACS Nano"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16050654","article-title":"Extracellular vesicles in breast cancer: From intercellular communication to therapeutic opportunities","volume":"16","author":"Muttiah","year":"2024","journal-title":"Pharmaceutics"},{"key":"B86","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41571-025-01074-2","article-title":"Clinical relevance of extracellular vesicles in cancer - therapeutic and diagnostic potential","volume":"22","author":"Greening","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12943-019-0980-8","article-title":"Extracellular vesicles in the tumor microenvironment: old stories, but new tales","volume":"18","author":"Han","year":"2019","journal-title":"Mol Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01463-y","article-title":"Cancer associated-fibroblast-derived exosomes in cancer progression","volume":"20","author":"Li","year":"2021","journal-title":"Mol Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-024-01577-y","article-title":"Harnessing extracellular vesicles using liquid biopsy for cancer diagnosis and monitoring: highlights from AACR annual meeting 2024","volume":"17","author":"Su","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12015-025-10940-6","article-title":"Development of a high-throughput morphological assay for evaluating mesenchymal stromal cell-derived extracellular vesicle modulation of brain pericyte secretory phenotype","volume":"21","author":"Campagna","year":"2025","journal-title":"Stem Cell Rev Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1007\/s12094-023-03115-7","article-title":"Mesenchymal stem cells-derived secretome and extracellular vesicles: perspective and challenges in cancer therapy and clinical applications","volume":"25","author":"Gemayel","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112820","article-title":"Extracellular vesicles reshape the tumor microenvironment to improve cancer immunotherapy: current knowledge and future prospects","volume":"140","author":"Hang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s40001-024-01937-x","article-title":"Therapeutic potential of extracellular vesicles from diverse sources in cancer treatment","volume":"29","author":"Lin","year":"2024","journal-title":"Eur J Med Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-023-00638-7","article-title":"Small extracellular vesicle TGF-\u03b2 in cancer progression and immune evasion","volume":"30","author":"Hosseini","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12484","article-title":"Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer","volume":"13","author":"Yao","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189101","article-title":"Extracellular vesicles in cancer therapy: roles, potential application, and challenges","volume":"1879","author":"Liu","year":"2024","journal-title":"BBA-Rev Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20517\/cdr.2024.152","article-title":"Cancer-associated fibroblast-derived EVs: regulators and therapeutic targets in the TME","volume":"8","author":"Xie","year":"2025","journal-title":"Cancer Drug Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jshs.2025.101041","article-title":"Exercise-induced EVs delay tumor development by igniting inflammation in an immunologically cold triple-negative breast cancer mouse model","volume":"14","author":"Mlynska","year":"2025","journal-title":"J Sport Health Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41556-019-0299-0","article-title":"Extracellular vesicle-packaged HIF-1\u03b1-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells","volume":"21","author":"Chen","year":"2019","journal-title":"Nat Cell Biol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s00262-025-04109-w","article-title":"T cell-derived small EVs in cancer\u2013immune interactions","volume":"74","author":"Garcia","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888713","article-title":"Shaping polarization of tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010132","article-title":"EVs as mediators of therapy resistance in the breast cancer microenvironment","volume":"12","author":"Samuels","year":"2022","journal-title":"Biomolecules"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41423-022-00926-6","article-title":"Tumor EVs mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1","volume":"19","author":"Chen","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040749","article-title":"EVs: Emerging modulators of cancer drug resistance","volume":"13","author":"Fontana","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41698-022-00287-3","article-title":"Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns","volume":"6","author":"Yu","year":"2022","journal-title":"Precis Onc"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf283.2224","article-title":"PD-L1 in tumor-derived extracellular vesicles promotes T-cell senescence and suppression of tumor immunity 4555","volume":"214","author":"Zhang","year":"2025","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001698","article-title":"Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1","volume":"9","author":"Yin","year":"2021","journal-title":"J Immunotherapy Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1038\/s41467-024-48200-9","article-title":"PD-1\/CD80+ small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1158\/2326-6066.CIR-22-0540","article-title":"Antigen-loaded extracellular vesicles induce responsiveness to anti\u2013PD-1 and anti\u2013PD-L1 treatment in a checkpoint refractory melanoma model","volume":"11","author":"Veerman","year":"2023","journal-title":"Cancer Immunores"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110022","article-title":"Extracellular vesicles-powered immunotherapy: unleashing the potential for safer and more effective cancer treatment","volume":"1","author":"Tiwari","year":"2024","journal-title":"Arch Biochem Biophys"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202516348","article-title":"PD-L1 on tumor-derived EVs induces CD8+ T cell terminal exhaustion and mediates anti-PD-1 resistance in head and neck squamous cell carcinoma","volume":"13","author":"Fang","year":"2026","journal-title":"Adv Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101922","article-title":"MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2455722","DOI":"10.1080\/15384047.2025.2455722","article-title":"Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell-derived EVs","volume":"26","author":"Castagnino","year":"2025","journal-title":"Cancer Biol Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.vesic.2024.100039","article-title":"Extracellular vesicles for breast cancer diagnosis and therapy","volume":"3","author":"Shi","year":"2024","journal-title":"Extracellular Vesicle"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040337","article-title":"EVs, circulating tumor cells, and immune checkpoint inhibitors: hints and promises","volume":"13","author":"Bandini","year":"2024","journal-title":"Cells"},{"key":"B117","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12951-025-03467-y","article-title":"In situ and dynamic screening of EVs as predictive biomarkers in immune-checkpoint inhibitor therapies","volume":"23","author":"Wang","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-022-02379-1","article-title":"Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer","volume":"41","author":"de Miguel-Perez","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.948959","article-title":"MicroRNAs in extracellular vesicles: sorting mechanisms, diagnostic value, isolation, and detection technology","volume":"10","author":"Xu","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12575-024-00241-6","article-title":"MicroRNA nano-shuttles: engineering extracellular vesicles as a cutting-edge biotechnology platform for clinical use in therapeutics","volume":"26","author":"Menjivar","year":"2024","journal-title":"Biol Proced Online"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/biom16020243","article-title":"Tyrosine\u2013peptide analog modulates extracellular vesicles miRNAs cargo from mesenchymal stem\/stromal and cancer cells to drive immunoregeneration and tumor suppression","volume":"16","author":"BRG Ley","year":"2026","journal-title":"Biomolecules"},{"key":"B122","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1021\/acsbiomaterials.4c00821","article-title":"Enhanced extracellular vesicle cargo loading via microRNA biogenesis pathway modulation","volume":"62","author":"Pottash","year":"2024","journal-title":"ACS Biomater Sci Eng"},{"key":"B123","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12938-024-01311-2","article-title":"Streamlined miRNA loading of surface protein-specific extracellular vesicle subpopulations through electroporation","volume":"23","author":"Torabi","year":"2024","journal-title":"BioMed Eng Online"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1016\/j.apsb.2025.04.033","article-title":"EVs as biomarkers and drug delivery systems for tumor","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2025.216718","article-title":"Biocompatible lipid nanovehicles for preventive and therapeutic vaccine development","volume":"538","author":"Jia","year":"2025","journal-title":"Coord Chem Rev"},{"key":"B126","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/EXP.20230171","article-title":"Tumor cell membrane\u2010based vaccines: a potential boost for cancer immunotherapy","volume":"4","author":"Yang","year":"2024","journal-title":"In Explor"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020257","article-title":"Extracellular vesicle-based strategies for tumor immunotherapy","volume":"17","author":"Jiramonai","year":"2025","journal-title":"Pharmaceutics"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102825","article-title":"EVs as biomarkers in cancer immunotherapy","volume":"12","author":"Mathew","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1007\/s13346-023-01370-3","article-title":"Extracellular vesicle\u2013based drug delivery in cancer immunotherapy","volume":"13","author":"Najafi","year":"2023","journal-title":"Drug Delivery Transl Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by extracellular vesicles: where we are and where we need to go","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030537","article-title":"Extracellular vesicles in cancer: mechanistic insights and clinical applications","volume":"18","author":"Alhumaydhi","year":"2026","journal-title":"Cancers"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.70078","article-title":"See the unseen: rapid, multiparametric single-particle analysis of EVs with nano-flow cytometry","volume":"10","author":"Hu","year":"2025","journal-title":"Proteomics"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12079","article-title":"Characterization of EVs and synthetic nanoparticles with four orthogonal single-particle analysis platforms","volume":"10","author":"Arab","year":"2021","journal-title":"J Extracell Vesicles"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41596-021-00551-z","article-title":"Using single-vesicle technologies to unravel the heterogeneity of extracellular vesicles","volume":"16","author":"Bordanaba-Florit","year":"2021","journal-title":"Nat Protoc"},{"key":"B135","doi-asserted-by":"publisher","first-page":"28021","DOI":"10.1021\/acsnano.5c00706","article-title":"Extracellular vesicles for clinical diagnostics: from bulk measurements to single-vesicle analysis","volume":"19","author":"Tran","year":"2025","journal-title":"ACS Nano"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/cells15030304","article-title":"Artificial intelligence for exosomal biomarker discovery for cardiovascular diseases: multi-omics integration, reproducibility, and translational prospects","volume":"15","author":"Dinc","year":"2026","journal-title":"Cells"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70078","article-title":"Integrating mass spectrometry\u2010based multi\u2010omic signatures of extracellular vesicles: from discovery to clinical translation","volume":"15","author":"Wijerathna\u2010Yapa","year":"2026","journal-title":"Clin Trans Immuno"},{"key":"B138","doi-asserted-by":"publisher","first-page":"D1807","DOI":"10.1093\/nar\/gkaf1189","article-title":"SVAtlas: a comprehensive single extracellular vesicle omics resource","volume":"54","author":"Wei","year":"2026","journal-title":"Nucleic Acids Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/molecules31020227","article-title":"Advanced technologies in extracellular vesicle biosensing: platforms, standardization, and clinical translation","volume":"31","author":"Choi","year":"2026","journal-title":"Molecules"},{"key":"B140","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/ejcrp.eJCRP-D-23-00030","article-title":"Spatial profiles in triple-negative breast cancer: unraveling the TME and biomarkers for immune checkpoint inhibitors","volume":"11","author":"Wu","year":"2024","journal-title":"J Cancer Res Pract"},{"key":"B141","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12967-021-03113-9","article-title":"The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling","volume":"19","author":"Schlam","year":"2021","journal-title":"J Transl Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J Clin Invest"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.433","article-title":"Integrated transcriptomics, proteomics, and functional analysis to characterize the tissue-specific small extracellular vesicle network of breast cancer","volume":"4","author":"Shen","year":"2023","journal-title":"MedComm (Beijing)"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006290","article-title":"Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies","volume":"11","author":"Magr\u00e9","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B145","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.2147\/IJN.S520791","article-title":"Multimodal imaging of brain metastasis-derived EVs using superparamagnetic iron oxide nanoparticle labeling","volume":"20","author":"Feginn Berle","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202502680","article-title":"Endogenous fluorescence labeling of EVs with a hydrophilic cyanine dye via caveolin-1 dependent endocytosis","volume":"14","author":"Park","year":"2025","journal-title":"Adv Healthc Mater"},{"key":"B147","doi-asserted-by":"publisher","first-page":"24012","DOI":"10.1073\/pnas.1909243116","article-title":"Label-free visualization and characterization of EVs in breast cancer","volume":"116","author":"You","year":"2019","journal-title":"Proc Nat Aca Sci"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30030498","article-title":"EVs as mediators and potential targets in combating cancer drug resistance","volume":"30","author":"Zhang","year":"2025","journal-title":"Molecules"},{"key":"B149","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41580-022-00460-3","article-title":"Challenges and directions in studying cell\u2013cell communication by EVs","volume":"23","author":"van Niel","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"EVs as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1204224","article-title":"Serum-derived EVs from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes","volume":"14","author":"Graham","year":"2023","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-025-03403-w","article-title":"Harnessing engineered EVs for enhanced therapeutic efficacy: advancements in cancer immunotherapy","volume":"44","author":"Gong","year":"2025","journal-title":"J Exp Cli Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1592006","article-title":"Current trends in theranostic applications of EVs in cancer","volume":"15","author":"Almasry","year":"2025","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872143\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:52Z","timestamp":1784180272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872143\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":153,"alternative-id":["10.3389\/fimmu.2026.1872143"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1872143","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1872143"}}